Advertisement
NRIX vs SKYE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NRIX is a StrongBuy and SKYE is a Buy.
NRIX in upward trend: price rose above 50-day moving average on October 20, 2026
NRIX moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 31 of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on NRIX as a result. In 70 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for NRIX just turned positive on October 14, 2026. Looking at past instances where NRIX's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
Following a +6.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in 204 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for NRIX moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 20 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for NRIX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
NRIX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NRIX entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. NRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.707) is normal, around the industry mean (2.988). P/E Ratio (-7.520) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (68.493) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SKYE in upward trend: price may jump up because it broke its lower Bollinger Band on October 13, 2026
SKYE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 42 of 49 cases where SKYE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 68 cases where SKYE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for SKYE just turned positive on September 21, 2026. Looking at past instances where SKYE's MACD turned positive, the stock continued to rise in 31 of 39 cases over the following month. The odds of a continued upward trend are 79%.
Following a +6.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where SKYE advanced for three days, in 203 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SKYE as a result. In 84 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SKYE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SKYE entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-14.512) is normal, around the industry mean (2.988). P/E Ratio (-0.159) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.130) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. SKYE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SKYE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NRIX | SKYE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 36 | 91 | |
P/E GROWTH RATING 1..100 | 58 | 7 | |
SEASONALITY SCORE 1..100 | 90 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SKYE's Valuation (10) in the null industry is somewhat better than the same rating for NRIX (57). This means that SKYE’s stock grew somewhat faster than NRIX’s over the last 12 months.
SKYE's Profit vs Risk Rating (100) in the null industry is in the same range as NRIX (100). This means that SKYE’s stock grew similarly to NRIX’s over the last 12 months.
NRIX's SMR Rating (98) in the null industry is in the same range as SKYE (100). This means that NRIX’s stock grew similarly to SKYE’s over the last 12 months.
NRIX's Price Growth Rating (36) in the null industry is somewhat better than the same rating for SKYE (91). This means that NRIX’s stock grew somewhat faster than SKYE’s over the last 12 months.
SKYE's P/E Growth Rating (7) in the null industry is somewhat better than the same rating for NRIX (58). This means that SKYE’s stock grew somewhat faster than NRIX’s over the last 12 months.
| NRIX | SKYE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | N/A |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 90% |
| Advances ODDS (%) | 3 days ago 82% | 2 days ago 83% |
| Declines ODDS (%) | 10 days ago 87% | 4 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NRIX’s FA Score shows that 0 FA rating(s) are green while SKYE’s FA Score has 2 green FA rating(s).
- NRIX’s FA Score: 0 green, 5 red.
- SKYE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NRIX’s TA Score shows that 4 TA indicator(s) are bullish while SKYE’s TA Score has 4 bullish TA indicator(s).
- NRIX’s TA Score: 4 bullish, 6 bearish.
- SKYE’s TA Score: 4 bullish, 3 bearish.
Price Growth
NRIX (@Biotechnology) experienced а +9.93% price change this week, while SKYE (@Biotechnology) price change was +3.82% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
NRIX is expected to report earnings on Feb 17, 2027.
SKYE is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NRIX and
Correlation & Price change
A.I.dvisor indicates that over the last year, NRIX has been loosely correlated with KYMR. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if NRIX jumps, then KYMR could also see price increases.
| Ticker / NAME | Correlation To NRIX | 1D Price Change % | ||
|---|---|---|---|---|
| NRIX | 100% | -0.31% | ||
| KYMR - NRIX | 59% Loosely correlated | -0.73% | ||
| GPCR - NRIX | 48% Loosely correlated | -3.80% | ||
| DYN - NRIX | 46% Loosely correlated | -1.23% | ||
| SVRA - NRIX | 44% Loosely correlated | -1.89% | ||
| AGIO - NRIX | 44% Loosely correlated | +1.47% | ||
More | ||||
SKYE and
Correlation & Price change
A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with VKTX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then VKTX could also see price increases.
| Ticker / NAME | Correlation To SKYE | 1D Price Change % | ||
|---|---|---|---|---|
| SKYE | 100% | +0.62% | ||
| VKTX - SKYE | 34% Loosely correlated | -1.24% | ||
| ABOS - SKYE | 30% Poorly correlated | +0.74% | ||
| RCKT - SKYE | 30% Poorly correlated | -5.98% | ||
| IPSC - SKYE | 29% Poorly correlated | -1.83% | ||
| NRIX - SKYE | 28% Poorly correlated | -0.31% | ||
More | ||||